{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:54:15Z","timestamp":1791057255990,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014008","name":"Ovarian Cancer Research Alliance","doi-asserted-by":"publisher","award":["2024-3-1553"],"award-info":[{"award-number":["2024-3-1553"]}],"id":[{"id":"10.13039\/100014008","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002956","name":"Foundation for Women&apos;s Cancer","doi-asserted-by":"publisher","award":["2025-2026"],"award-info":[{"award-number":["2025-2026"]}],"id":[{"id":"10.13039\/100002956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021369","name":"OCRA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021369","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ygyno.2026.09.006","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:47:38Z","timestamp":1790110058000},"page":"7-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Immunotherapy-induced thyroid dysfunction and diabetes mellitus in gynecologic oncology patients: a retrospective cohort study"],"prefix":"10.1016","volume":"214","author":[{"given":"Anna","family":"Gonzalez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Chalif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reed","family":"O'Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Morton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Fulton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Velasquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey M.","family":"Cosgrove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry J.","family":"Copeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa I.","family":"Nagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floor","family":"Backes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"O'Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2026.09.006_bb0005","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/GRF.0000000000000513","article-title":"Immunotherapy for gynecologic cancer: current applications and future directions","volume":"63","author":"Lynam","year":"2020","journal-title":"Clin. Obstet. Gynecol."},{"issue":"21","key":"10.1016\/j.ygyno.2026.09.006_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215205","article-title":"Role of immunotherapy in the treatment of cancer: a systematic review","volume":"14","author":"Ling","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"20","key":"10.1016\/j.ygyno.2026.09.006_bb0015","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10434","key":"10.1016\/j.ygyno.2026.09.006_bb0020","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.ygyno.2026.09.006_bb0025","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.ygyno.2026.09.006_bb0030","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ygyno.2026.09.006_bb0035","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4103\/apjon.apjon_4_17","article-title":"Immune checkpoint inhibitors: an innovation in immunotherapy for the treatment and management of patients with cancer","volume":"4","author":"Dine","year":"2017","journal-title":"Asia Pac. J. Oncol. Nurs."},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.006_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2019.101370","article-title":"New insight in endocrine-related adverse events associated to immune checkpoint blockade","volume":"34","author":"Elia","year":"2020","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.ygyno.2026.09.006_bb0045","article-title":"The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management","volume":"2","author":"Girotra","year":"2018","journal-title":"JNCI Cancer Spectr."},{"issue":"3","key":"10.1016\/j.ygyno.2026.09.006_bb0050","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"de Filette","year":"2019","journal-title":"Horm. Metab. Res."},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.006_bb0055","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","article-title":"Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system","volume":"7","author":"Zhai","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"36","key":"10.1016\/j.ygyno.2026.09.006_bb0060","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2026.09.006_bb0065","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.006_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010246","article-title":"Management of endocrine and metabolic toxicities of immune-checkpoint inhibitors: from clinical studies to a real-life scenario","volume":"15","author":"Spagnolo","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"14","key":"10.1016\/j.ygyno.2026.09.006_bb0075","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.2174\/0118715303280679240206100137","article-title":"Endocrine adverse events related to immune checkpoint inhibitor treatment: relationship between antibodies and severity of thyroid dysfunction","volume":"24","author":"Gonzalez","year":"2024","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"4","key":"10.1016\/j.ygyno.2026.09.006_bb0080","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s42000-024-00535-0","article-title":"Challenges and pitfalls in the management of endocrine toxicities from immune checkpoint inhibitors: a case presentation of synchronous thyrotoxicosis and primary adrenal insufficiency in a melanoma patient","volume":"23","author":"Spagnolo","year":"2024","journal-title":"Hormones (Athens)"},{"issue":"11","key":"10.1016\/j.ygyno.2026.09.006_bb0085","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1007\/s40618-023-02096-2","article-title":"Predictors of thyroid adverse events during cancer immunotherapy: a real-life experience at a single center","volume":"46","author":"Ruggeri","year":"2023","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.ygyno.2026.09.006_bb0090","article-title":"Clinical manifestations and risk factors of immune-related thyroid adverse events in patients treated with PD-1 inhibitors: a case-control study","volume":"16","author":"Zhao","year":"2025","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.09.006_bb0095","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2026.09.006_bb0100","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.006_bb0105","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr. Rev."},{"issue":"13","key":"10.1016\/j.ygyno.2026.09.006_bb0110","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.21.02377","article-title":"Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials","volume":"40","author":"Unger","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.09.006_bb0115","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J. Biomed. Inform."},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2026.09.006_bb0120","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.2337\/dc24-S002","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice C","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ygyno.2026.09.006_bb0125","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","author":"U.S. Department of Health and Human Services NIoH, National Cancer Institute","year":"2017"},{"issue":"2","key":"10.1016\/j.ygyno.2026.09.006_bb0130","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3109\/08830185.2015.1018417","article-title":"Sex-driven differences in immunological responses: challenges and opportunities for the immunotherapies of the third millennium","volume":"34","author":"Mirandola","year":"2015","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.ygyno.2026.09.006_bb0135","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3389\/fimmu.2018.00552","article-title":"Sexual dimorphism of immune responses: a new perspective in cancer immunotherapy","volume":"9","author":"Capone","year":"2018","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.ygyno.2026.09.006_bb0140","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1056\/NEJMra1901214","article-title":"Drug effects on the thyroid","volume":"381","author":"Burch","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ygyno.2026.09.006_bb0145","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jamaoncol.2024.6473","article-title":"Concerns in interpretation of results in the identification of immune checkpoint inhibitor-induced diabetes","volume":"11","author":"Akturk","year":"2025","journal-title":"JAMA Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2026.09.006_bb0150","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jamaoncol.2024.3104","article-title":"Identification of immune checkpoint inhibitor-induced diabetes","volume":"10","author":"Ruiz-Esteves","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2026.09.006_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.ygyno.2026.09.006_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102590","article-title":"Immune checkpoint inhibitors-induced autoimmunity: the impact of gender","volume":"19","author":"Triggianese","year":"2020","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.ygyno.2026.09.006_bb0165","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s12020-021-02750-w","article-title":"Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy","volume":"74","author":"Rubino","year":"2021","journal-title":"Endocrine"},{"issue":"26","key":"10.1016\/j.ygyno.2026.09.006_bb0170","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2026.09.006_bb0175","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","article-title":"Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial","volume":"24","author":"Llovet","year":"2023","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2026.09.006_bb0180","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/oncolo\/oyac269","article-title":"Characterization and management of adverse reactions from the CLEAR study in advanced renal cell carcinoma treated with Lenvatinib plus pembrolizumab","volume":"28","author":"Motzer","year":"2023","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.ygyno.2026.09.006_bb0185","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1470-2045(23)00276-0","article-title":"Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial","volume":"24","author":"Albiges","year":"2023","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.09.006_bb0190","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.tem.2021.10.009","article-title":"The changing clinical spectrum of endocrine adverse events in cancer immunotherapy","volume":"33","author":"Chiloiro","year":"2022","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.ygyno.2026.09.006_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40842-018-0073-4","article-title":"Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports","volume":"5","author":"Tan","year":"2019","journal-title":"Clin. Diabetes Endocrinol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826021293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826021293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:36:31Z","timestamp":1791056191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826021293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":39,"alternative-id":["S0090825826021293"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.09.006","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy-induced thyroid dysfunction and diabetes mellitus in gynecologic oncology patients: a retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}